As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.

GLP-1 receptor agonists, originally developed for managing type 2 diabetes ... By reducing hunger and promoting a feeling of ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

Interim data from initial dose escalation cohorts of Phase 1 CARDINAL ... for an oral GLP-1R agonist Low solubility and high gut permeability allowed for prolonged absorption and sustained target ...

The drug semaglutide, commonly known by the brand names Ozempic or Wegovy, was originally developed to help people with type 2 diabetes manage their blood sugar levels. However, researchers have ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes ... By reducing hunger and promoting a feeling of ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...